Korsana Biosciences, Inc. (KRSA): R&D Expense
$959.0K
Year ended 2025-12-31
$1.60M
Trailing 12 months to 2026-06-30
-45.7%
3-year compound annual growth
-55.7%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $959.0K | +235.3% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $286.0K | -81.1% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $1.51M | -74.7% | 2025-11-12, From 2023-01-01 |
| 2022-12-31 | $5.98M | -84.1% | 2024-03-05, From 2022-01-01 |
| 2021-12-31 | $37.64M | -33.3% | 2023-03-22, From 2021-01-01 |
| 2020-12-31 | $56.41M | -40.7% | 2022-02-24, From 2020-01-01 |
| 2019-12-31 | $95.14M | +8.5% | 2021-02-25, From 2019-01-01 |
| 2018-12-31 | $87.72M | n/a | 2020-03-12, From 2018-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Korsana Biosciences, Inc. (KRSA) | 2025-12-31 | $959.0K | +235.3% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $145.64M | +75.2% |
| Lipocine Inc. (LPCN) | 2025-12-31 | $8.58M | +16.8% |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | $18.12M | -23.6% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $20.20M | -24.3% |
| Cartesian Therapeutics, Inc. (RNAC) | 2025-12-31 | $58.03M | +28.7% |
| Upstream Bio, Inc. (UPB) | 2025-12-31 | $136.81M | +117.3% |
| Xenetic Biosciences, Inc. (XBIO) | 2025-12-31 | $3.07M | -6.8% |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $3.78M | -39.1% |
Compare KRSA, DNTH, LPCN, GOVX side by side · Screen every company in Pharmaceutical Preparations ↗